Melatonin reduces ulcerative colitis-associated local and systemic damage in mice: Investigation on possible mechanisms

Digestive Diseases and Sciences

Volumn 58, Issue 12, 2013, Pages 3460-3474

  Trivedi, P P ^a   Jena, G B ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Genotoxicity; Inflammation; Lipopolysaccharide; Melatonin; Oxidative stress; Ulcerative colitis

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; CYCLOOXYGENASE 2; DEXTRAN SULFATE; DRINKING WATER; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; LIPOPOLYSACCHARIDE; MELATONIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR NRF2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD LEVEL; COMET ASSAY; CONTROLLED STUDY; DISEASE SEVERITY; DNA DAMAGE; DRUG EFFECT; DRUG MEGADOSE; EVENING DOSAGE; GENOTOXICITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTESTINE MUCOSA PERMEABILITY; MICRONUCLEUS TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH PROTECTION; ULCER HEALING; ULCERATIVE COLITIS; WESTERN BLOTTING;

ANIMALS; ANTIOXIDANTS; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; COLON; DEOXYGUANOSINE; DNA DAMAGE; LIPOPOLYSACCHARIDES; MALE; MELATONIN; MICE; OCCLUDIN; OXIDATIVE STRESS; PERMEABILITY; RANDOM ALLOCATION; SEVERITY OF ILLNESS INDEX;

EID: 84890130576     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2831-6     Document Type: Article

References (75)

1. Eijkelkamp N, Heijnen CJ, Lucas A, et al. G protein-coupled receptor kinase 6 controls chronicity and severity of dextran sodium sulphate-induced colitis in mice. Gut. 2007;56:847-854.
2. Engel MA, Neurath MF. New pathophysiological insights and modern treatment of IBD. J Gastroenterol. 2010;45:571-583.
3. Makharia GK, Ramakrishna BS, Abraham P, et al. Survey of inflammatory bowel diseases in India. Indian J Gastroenterol. 2012;31:299-306.
4. Algieri F, Zorrilla P, Rodriguez-Nogales A, et al. Intestinal anti-inflammatory activity of hydroalcoholic extracts of Phlomis purpurea L. and Phlomis lychnitis L. in the trinitrobenzenesulphonic acid model of rat colitis. J Ethnopharmacol. 2013;146:750-759.
5. Lee MJ, Lee JK, Choi JW, et al. Interleukin-6 induces S100A9 expression in colonic epithelial cells through STAT3 activation in experimental ulcerative colitis. PLoS ONE. 2012;7:e38801.
6. Radema SA, van Deventer SJ, Cerami A. Interleukin 1 beta is expressed predominantly by enterocytes in experimental colitis. Gastroenterology. 1991;100:1180-1186.
7. Trivedi PP, Jena GB. Dextran sulfate sodium-induced ulcerative colitis leads to increased hematopoiesis and induces both local as well as systemic genotoxicity in mice. Mutat Res. 2012;744:172-183.
8. Kaspar JW, Niture SK, Jaiswal AK. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med. 2009;47:1304-1309.
9. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol. 2004;4:617-629.
10. Toedter G, Li K, Sague S, et al. Genes associated with intestinal permeability in ulcerative colitis: changes in expression following infliximab therapy. Inflamm Bowel Dis. 2012;18:1399-1410.
11. Trivedi PP, Jena GB. Ulcerative colitis-induced hepatic damage in mice: studies on inflammation, fibrosis, oxidative DNA damage and GST-P expression. Chem Biol Interact. 2013;201:19-30.
12. Gabele E, Dostert K, Hofmann C, et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol. 2011;55:1391-1399.
13. Villaran RF, Espinosa-Oliva AM, Sarmiento M, et al. Ulcerative colitis exacerbates lipopolysaccharide-induced damage to the nigral dopaminergic system: potential risk factor in Parkinson's disease. J Neurochem. 2010;114:1687-1700.
14. Jena GB, Trivedi PP, Sandala B. Oxidative stress in ulcerative colitis: an old concept but a new concern. Free Radic Res. 2012;46:1339-1345.
15. Westbrook AM, Wei B, Braun J, et al. Intestinal mucosal inflammation leads to systemic genotoxicity in mice. Cancer Res. 2009;69:4827-4834.
16. Tan DX, Manchester LC, Hardeland R, et al. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res. 2003;34:75-78.
17. Nosal'ova V, Zeman M, Cerna S, et al. Protective effect of melatonin in acetic acid induced colitis in rats. J Pineal Res. 2007;42:364-370.
18. Bubenik GA. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci. 2002;47:2336-2348.
19. Bonnefont-Rousselot D, Collin F, Jore D, et al. Reaction mechanism of melatonin oxidation by reactive oxygen species in vitro. J Pineal Res. 2011;50:328-335.
20. Galano A, Tan DX, Reiter RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res. 2011;51:1-16.
21. Marchetti C, Sidahmed-Adrar N, Collin F, et al. Melatonin protects PLPC liposomes and LDL towards radical-induced oxidation. J Pineal Res. 2011;51:286-296.
22. Tan DX, Reiter RJ, Manchester LC, et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem. 2002;2:181-197.
23. Gitto E, Tan DX, Reiter RJ, et al. Individual and synergistic antioxidative actions of melatonin: studies with vitamin E, vitamin C, glutathione and desferrioxamine (desferoxamine) in rat liver homogenates. J Pharm Pharmacol. 2001;53:1393-1401.
24. Carrillo-Vico A, Guerrero JM, Lardone PJ, et al. A review of the multiple actions of melatonin on the immune system. Endocrine. 2005;27:189-200.
25. Carrillo-Vico A, Reiter RJ, Lardone PJ, et al. The modulatory role of melatonin on immune responsiveness. Curr Opin Investig Drugs. 2006;7:423-431.
26. Chuang JI, Mohan N, Meltz ML, et al. Effect of melatonin on NF-kappa-B DNA-binding activity in the rat spleen. Cell Biol Int. 1996;20:687-692.
27. De Filippis D, Iuvone T, Esposito G, et al. Melatonin reverses lipopolysaccharide-induced gastro-intestinal motility disturbances through the inhibition of oxidative stress. J Pineal Res. 2008;44:45-51.
28. Mohan N, Sadeghi K, Reiter RJ, et al. The neurohormone melatonin inhibits cytokine, mitogen and ionizing radiation induced NF-kappa B. Biochem Mol Biol Int. 1995;37:1063-1070.
29. Cuzzocrea S, Mazzon E, Serraino I, et al. Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. J Pineal Res. 2001;30:1-12.
30. Esposito E, Mazzon E, Riccardi L, et al. Matrix metalloproteinase-9 and metalloproteinase-2 activity and expression is reduced by melatonin during experimental colitis. J Pineal Res. 2008;45:166-173.
31. Mazzon E, Esposito E, Crisafulli C, et al. Melatonin modulates signal transduction pathways and apoptosis in experimental colitis. J Pineal Res. 2006;41:363-373.
32. Tasdemir S, Parlakpinar H, Vardi N, et al. Effect of endogen-exogenous melatonin and erythropoietin on dinitrobenzene sulfonic acid-induced colitis. Fundam Clin Pharmacol. 2013;27:299-307.
33. Chojnacki C, Wisniewska-Jarosinska M, Walecka-Kapica E, et al. Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis. J Physiol Pharmacol. 2011;62:327-334.
34. Rakhimova O. Use of melatonin in combined treatment for inflammatory bowel diseases. Ter Arkh. 2010;82:64-68.
35. Dong WG, Mei Q, Yu JP, et al. Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. World J Gastroenterol. 2003;9:1307-1311.
36. Tahan G, Gramignoli R, Marongiu F, et al. Melatonin expresses powerful anti-inflammatory and antioxidant activities resulting in complete improvement of acetic-acid-induced colitis in rats. Dig Dis Sci. 2011;56:715-720.
37. Akcan A, Kucuk C, Sozuer E, et al. Melatonin reduces bacterial translocation and apoptosis in trinitrobenzene sulphonic acid-induced colitis of rats. World J Gastroenterol. 2008;14:918-924.
38. Li JH, Yu JP, Yu HG, et al. Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediators Inflamm. 2005;2005:185-193.
39. Li JH, Zhou W, Liu K, et al. Melatonin reduces the expression of chemokines in rat with trinitrobenzene sulfonic acid-induced colitis. Saudi Med J. 2008;29:1088-1094.
40. Necefli A, Tulumoglu B, Giris M, et al. The effect of melatonin on TNBS-induced colitis. Dig Dis Sci. 2006;51:1538-1545.
41. Mei Q, Xu JM, Xiang L, et al. Change of nitric oxide in experimental colitis and its inhibition by melatonin in vivo and in vitro. Postgrad Med J. 2005;81:667-672.
42. Mei Q, Yu JP, Xu JM, et al. Melatonin reduces colon immunological injury in rats by regulating activity of macrophages. Acta Pharmacol Sin. 2002;23:882-886.
43. Pentney PT, Bubenik GA. Melatonin reduces the severity of dextran-induced colitis in mice. J Pineal Res. 1995;19:31-39.
44. Motilva V, Garcia-Maurino S, Talero E, et al. New paradigms in chronic intestinal inflammation and colon cancer: role of melatonin. J Pineal Res. 2011;51:44-60.
45. Kim J, Cha YN, Surh YJ. A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutat Res. 2010;690:12-23.
46. Morioka N, Okatani Y, Wakatsuki A. Melatonin protects against age-related DNA damage in the brains of female senescence-accelerated mice. J Pineal Res. 1999;27:202-209.
47. Tripathi A, PremKumar KV, Pandey AN, et al. Melatonin protects against clomiphene citrate-induced generation of hydrogen peroxide and morphological apoptotic changes in rat eggs. Eur J Pharmacol. 2011;667:419-424.
48. Chava VK, Sirisha K. Melatonin: a novel indolamine in oral health and disease. Int J Dent. 2012;2012:720185.
49. Forman K, Vara E, Garcia C, et al. Beneficial effects of melatonin on cardiological alterations in a murine model of accelerated aging. J Pineal Res. 2010;49:312-320.
50. Tripathi DN, Jena GB. Effect of melatonin on the expression of Nrf2 and NF-kappaB during cyclophosphamide-induced urinary bladder injury in rat. J Pineal Res. 2010;48:324-331.
51. Rachmilewitz D, Simon PL, Schwartz LW, et al. Inflammatory mediators of experimental colitis in rats. Gastroenterology. 1989;97:326-337.
52. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
53. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351-358.
54. Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta. 1979;582:67-78.
55. Dadhania VP, Tripathi DN, Vikram A, et al. Intervention of alpha-lipoic acid ameliorates methotrexate-induced oxidative stress and genotoxicity: a study in rat intestine. Chem Biol Interact. 2010;183:85-97.
56. Kasamatsu T, Kohda K, Kawazoe Y. Comparison of chemically induced DNA breakage in cellular and subcellular systems using the comet assay. Mutat Res. 1996;369:1-6.
57. Speit G, Hartmann A. The comet assay (single-cell gel test). A sensitive genotoxicity test for the detection of DNA damage and repair. Methods Mol Biol. 1999;113:203-212.
58. Tripathi DN, Pawar AA, Vikram A, et al. Use of the alkaline comet assay for the detection of transplacental genotoxins in newborn mice. Mutat Res. 2008;653:134-139.
59. Collins AR, Duthie SJ, Dobson VL. Direct enzymic detection of endogenous oxidative base damage in human lymphocyte DNA. Carcinogenesis. 1993;14:1733-1735.
60. Holden HE, Majeska JB, Studwell D. A direct comparison of mouse and rat bone marrow and blood as target tissues in the micronucleus assay. Mutat Res. 1997;391:87-89.
61. Tanaka T, Yasui Y, Tanaka M, et al. Melatonin suppresses AOM/DSS-induced large bowel oncogenesis in rats. Chem Biol Interact. 2009;177:128-136.
62. Awney HA, Attih AM, Habib SL, et al. Effect of melatonin on the production of microsomal hydrogen peroxide and cytochrome P-450 content in rat treated with aflatoxin B(1). Toxicology. 2002;172:143-148.
63. Costantino G, Cuzzocrea S, Mazzon E, et al. Protective effects of melatonin in zymosan-activated plasma-induced paw inflammation. Eur J Pharmacol. 1998;363:57-63.
64. Huang F, Ning H, Xin QQ, et al. Melatonin pretreatment attenuates 2-bromopropane-induced testicular toxicity in rats. Toxicology. 2009;256:75-82.
65. Okatani Y, Wakatsuki A, Reiter RJ, et al. Protective effect of melatonin against mitochondrial injury induced by ischemia and reperfusion of rat liver. Eur J Pharmacol. 2003;469:145-152.
66. Patel V, Upaganlawar A, Zalawadia R, et al. Cardioprotective effect of melatonin against isoproterenol induced myocardial infarction in rats: a biochemical, electrocardiographic and histoarchitectural evaluation. Eur J Pharmacol. 2010;644:160-168.
67. Subramanian P, Mirunalini S, Pandi-Perumal SR, et al. Melatonin treatment improves the antioxidant status and decreases lipid content in brain and liver of rats. Eur J Pharmacol. 2007;571:116-119.
68. Dave M, Loftus EV Jr. Mucosal healing in inflammatory bowel disease-a true paradigm of success? Gastroenterol Hepatol (N Y). 2012;8:29-38.
69. Swarnakar S, Mishra A, Ganguly K, et al. Matrix metalloproteinase-9 activity and expression is reduced by melatonin during prevention of ethanol-induced gastric ulcer in mice. J Pineal Res. 2007;43:56-64.
70. Ganguly K, Swarnakar S. Induction of matrix metalloproteinase-9 and -3 in nonsteroidal anti-inflammatory drug-induced acute gastric ulcers in mice: regulation by melatonin. J Pineal Res. 2009;47:43-55.
71. Laothong U, Pinlaor P, Hiraku Y, et al. Protective effect of melatonin against Opisthorchis viverrini-induced oxidative and nitrosative DNA damage and liver injury in hamsters. J Pineal Res. 2010;49:271-282.
72. Qi W, Reiter RJ, Tan DX, et al. Inhibitory effects of melatonin on ferric nitrilotriacetate-induced lipid peroxidation and oxidative DNA damage in the rat kidney. Toxicology. 1999;139:81-91.
73. Westbrook AM, Wei B, Hacke K, et al. The role of tumour necrosis factor-alpha and tumour necrosis factor receptor signalling in inflammation-associated systemic genotoxicity. Mutagenesis. 2012;27:77-86.
74. Arthur JC, Perez-Chanona E, Muhlbauer M, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012;338:120-123.
75. Li Volti G, Musumeci T, Pignatello R, et al. Antioxidant potential of different melatonin-loaded nanomedicines in an experimental model of sepsis. Exp Biol Med (Maywood). 2012; 237:670-677.